Abstract
Recently, positron emission tomography (PET) imaging using PSMA-ligands has gained high attention as a promising new radiotracer in patients with prostate cancer (PC). Several studies promise accurate staging of primary prostate cancer and restaging after biochemical recurrence with 68Ga-PSMA ligand Positron emission tomography/computed tomography (PET/CT). However, prospective trials and clinical guidelines for this new technique are still missing. Therefore, we summarized our experience with 68Ga-PSMA ligand PET/CT examinations in patients with primary PC and biochemical recurrence. It focuses on the technical and logistical aspects of 68Ga-PSMA ligand PET/CT examination as well as on the specific background for image reading discussing also potential pitfalls. Further, it includes relevant issues on free-text as well as structured reporting used in daily clinical routine.
Original language | English |
---|---|
Article number | 14 |
Journal | Cancer Imaging |
Volume | 16 |
Issue number | 1 |
DOIs | |
State | Published - 8 Jun 2016 |
Externally published | Yes |
Keywords
- Positron emission tomography
- Prostate cancer
- Prostate specific membrane antigen